- New
- Out-of-Stock
RETATRUTIDE 10mg
£99.00
No tax
Retarutide is an active compound named Retarutide released by Lilly in June 2023. It is a developed drug for the treatment of obesity and type 2 diabetes, based on Tirzepatide, a GLP/GI dual receptor agonist, and achieves triple (GLP-1/GIP/Gcg) agonist effect by hybridizing glucagon related structures. This active compound can activate receptor agonists in our body, helping to control blood sugar and manage weight loss.
Comments (0)